Preclinical research has also demonstrated its sensitivity to the akt inhibitor miransertib in a patient-derived xenograft model of endometrial cancer harboring PIK3CA (p.D350G; p.R93W) and PTEN (p.R130G) mutations [59]. This evidence concerns the gene PIK3CA and endometrial cancer.